Erika Hamilton: This is the power of clinical trials!
Erika Hamilton shared a post by Mel Mann, a Patient Advocate for
“This is the power of clinical trials! Today’s trial drugs are the standard drugs of tomorrow. By utilizing trial options, patients often get access to drugs 5-10 years ahead of commercial approvals! They also advance care for all others to come behind them.”
Quoting Mel Mann’s post:
“From 37 to 67 : When I was 37 years old, I was diagnosed with Chronic Myeloid Leukemia (CML) and given 3 years to live. This April, I celebrate my 67th birthday, thanks to the phase 1 Novartis Gleevec clinical trial.
~ Mel Mann, World’s Longest Living Gleevec Survivor.”
Source: Erika Hamilton/LinkedIn and Mel Mann/LinkedIn
Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective. Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.